Jump to content [AK + s] Jump to navigation [AK + 3]

Annual Report 2014

English | Dutch
  • Twitter
  • LinkedIn

Primary Menu

  • The Galapagos Group
    • Letter from the CEO
    • At a glance
    • Strategy
    • Overview of Galapagos NV
    • Going concern statement
    • Risk management
    • The Galapagos share
    • Subsequent events
    • Disclaimer and other information
  • R&D
    • The Galapagos pipeline
    • Target discovery
    • Rheumatoid arthritis
    • Inflammatory bowel disease
    • Cystic fibrosis
    • IPF
  • Risk factors
    • Financial position and need for additional capital
    • Product development, regulatory approval and commercialization
    • Reliance on third parties
    • Competitive position
    • Intellectual property
    • Organization, structure and operation
    • Galapagos shares
    • General statement
  • Corporate governance
    • Policies
    • Board of Directors
    • Committees
    • Share capital and shares
    • Shareholders
    • Remuneration report
      • Determination
      • Policy
      • Non-executive Directors
      • Executive Directors
      • Criteria and methods to evaluate performance
      • Gross remuneration of CEO
      • Gross remuneration of other Executive Committee members
      • Shares, warrants or other rights
      • Contractual provisions
      • Severance payments
      • Claw-back right
    • Conflict of interests and related parties
    • Statement by the Board of Directors
  • Financial statements
    • Consolidated financial statements
      • Income statement and statement of comprehensive income
      • Statements of financial position
      • Cash flow statements
      • Statements of changes in equity
    • Non-consolidated financial statements
  • Notes
    • Notes to the consolidated financial statements
      • Notes 1-10
        • 1. General Information
        • 2. Significant accounting policies
        • 3. Segment information
        • 4. Total revenues and other income
        • 5. Operating costs
        • 6. Staff costs
        • 7. Finance income and expense
        • 8. Taxes
        • 9. Discontinued operations
        • 10. Result per share
      • Notes 11-20
        • 11. Goodwill
        • 12. Intangible assets
        • 13. Property, plant and equipment
        • 14. Research and Development incentives receivables
        • 15. Other non-currrent assets
        • 16. Restricted cash
        • 17. Inventory
        • 18. Trade and other receivables and other current assets
        • 19. Cash and cash equivalents
        • 20. Share capital
      • Notes 21-30
        • 21. Share premium
        • 22. Other reserves
        • 23. Translation differences
        • 24. Deferred tax
        • 25. Finance lease liabilities
        • 26. Trade and other payables
        • 27. Provisions
        • 28. Operating lease obligations
        • 29. Off-balance sheet arrangements
        • 30. Contingent assets and liabilities
      • Notes 31-40
        • 31. Retirement benefit plans
        • 32. Warrant plans
        • 33. Related parties
        • 34. Remuneration of key management personnel
        • 35. Consolidated companies as of 31 December 2014
        • 36. Company acquistions and disposals
        • 37. Critical accounting estimates and judgments
        • 38. Financial risk management
        • 39. Auditor’s remuneration
        • 40. Events after balance sheet date
    • Report of the statutory auditor
Galapagos is an innovator that discovers and develops novel treatments for patients suffering from diseases with high unmet medical needs.

Dr Piet Wigerinck

CSO of Galapagos

Risk factors

Risk factors

Description of the risks of which investors should be aware

previous pagenext page

Financial position and need for additional capital

Read more

Competitive position

Read more

Intellectual property

Read more
to page top

Service

  • Glossary of terms
  • Downloads
  • Financial calendar
  • Galapagos Corporate Website

Last Update 26 March 2015

Galapagos Annual Report 2014 (PDF)

Download the entire report as PDF.

Download PDF (8 MB)
  • © Copyright 2015 Galapagos NV
  • Colophon
  • Contact
  • Sitemap
nexxar - digital reporting evolved - Online Report